Durable Responses with Vemurafenib plus Rituximab in Hairy-Cell Leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-071
Abstract: Of 30 patients with relapsed or refractory hairy-cell leukemia, 87% experienced complete responses. read more here.
Keywords: responses vemurafenib; durable responses; cell leukemia; hairy cell ... See more keywords